Bicciato Giulio, Arnold Markus, Gebhardt Aidan, Katan Mira
Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Curr Opin Neurol. 2022 Feb 1;35(1):45-54. doi: 10.1097/WCO.0000000000001011.
One in eight patients unfortunately suffers a new stroke within 5 years of their first stroke, even today. Research in precision medicine could lead to a more individualized treatment allocation, possibly achieving lower recurrence rates of ischemic stroke. In this narrative review, we aim to discuss potential clinical implementation of several promising candidate blood biomarkers.
We discuss specifically some promising blood-based biomarkers, which may improve the identification of underlying causes as well as risk stratification of patients according to their specific cerebrovascular risk factor pattern.
Multimodal profiling of ischemic stroke patients by means of blood biomarkers, in addition to established clinical and neuroradiological data, may allow in the future a refinement of decision algorithms for treatment allocation in secondary ischemic stroke prevention.
不幸的是，即使在今天，每八名患者中仍有一人在首次中风后的5年内会再次中风。精准医学研究可能会带来更个性化的治疗分配，有望降低缺血性中风的复发率。在这篇叙述性综述中，我们旨在探讨几种有前景的血液生物标志物在临床中的潜在应用。
我们具体讨论了一些有前景的血液生物标志物，这些标志物可能有助于更好地识别潜在病因，并根据患者特定的脑血管危险因素模式进行风险分层。
除了已有的临床和神经放射学数据外，通过血液生物标志物对缺血性中风患者进行多模式分析，未来可能会优化二级缺血性中风预防中治疗分配的决策算法。
